Tarsus Pharmaceuticals Inc.

TARS

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

Driehaus Capital RTW Investments OrbiMed Advisors

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 1,172,427Value: $96.0M

**SIGNAL NOTE: Driehaus Capital initiates $96M position in TARS** Driehaus' entry into Tarsus signals confidence in Alhtabib (LDI for dry eye disease), which generated $29M in Q3 2024 revenue and is tracking toward $100M+ annual run-rate. The timing suggests conviction ahead of potential label expansion data or margin inflection as the product scales post-FDA approval (2023).

RTW InvestmentsNEWFeb 17, 2026

Shares: 3,335,320

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

PTCT4 funds INSM4 funds NBIX3 funds APLS3 funds ALNY3 funds AXSM3 funds ALKS3 funds ISRG

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: RTW Initiates $273M Position in TARS RTW's substantial entry into Tarsus signals confidence in the company's core asset, topical iota-carrageenan (FzeldenAlexandru), which is in Phase 3 development for dry eye disease (DED). The timing suggests conviction ahead of potential Phase 3 readouts expected in 2024-2025, a binary catalyst that could validate the topical antiviral approach in a large, underserved market where current therapies remain limited to symptom management.